Kliniken Ostalb gemeinnuetzige kommunale Anstalt des oeffentlichen Rechts — Clinical Trial Site

38 Registered trials

16 Currently recruiting

Organisation

Kliniken Ostalb gemeinnuetzige kommunale Anstalt des oeffentlichen Rechts

Location

Mutlangen, Germany

Identifier

ORG-100041965

Address

Wetzgauer Strasse 85, 73557, Germany

Departments

-
#5006:Zentrum Für Innere Medizin
Center for Internal Medicine
Frauenklinik
Hämatologie und Onkologie
Hämatologie und Onkologie Mutlangen
Hematology and oncology
Innere Medizin
Internal Medicine
Internal Medicine and Hematology
Internal medicine, division of hematology/oncology
Medizinische Klinik I
not applicable
Oncology Center
Onkologisches Zentrum
Schwerpunkt Hämatologie / Internistische Onkologie
Standort Stauferklinikum Schwäbisch Gmünd
Standort Stauferklinikum Schwäbisch Gmünd - Zentrum für Innere Medizin
Standort Stauferklinikum, Zentrum für Innere Medizin
Stauferklinikum Schwäbisch Gmünd
Stauferklinikum Schwäbisch Gmünd Zentrum für Innere Medizin
Zentrum fuer Innere Medizin
Zentrum für Innere Medizin
Zentrum für Innere Medizin, Hämatologie/ Onkologie
Zentrum Innere Medizin

Clinical trials at this site (38)

Search interface

Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Not authorised

2023-509861-19-00 Diffuse large B-cell lymphoma (DLBCL) 4
Stopping tyrosine kinase inhibitors a second or third time after unsuccesful treatment discontinuation in chronic myeloid leukemia Pending

2024-519472-69-00 CML-Patients in chronic phase having failed a prior att 4
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy with Standard-of-Care Combination Regimens … Pending

2024-519504-27-00 Relapsed Refractory Multiple Myeloma 5
A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-c… Recruiting

2023-507402-13-00 Multiple myeloma 5 2024-04-03
A trial to learn if odronextamab is safe and well-tolerated and how well it works compared to rituximab combined with different types of che… Recruiting

2022-502660-20-00 Follicular lymphoma 5 2024-01-23
A Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) plus BSC versus Placebo plus BSC in Participants with IPS… Recruiting

2022-500479-29-00 International Prognostic Scoring System-Revised (IPSS-R 10 2023-03-28
A PROSPECTIVE, OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE 3 TRIAL OF ACALABRUTINIB, OBINUTUZUMAB AND VENETOCLAX (GAVE) COMPARED TO OBINUTUZU… Recruiting

2023-506414-46-00 High risk patients defined as having at least one of th 5 2022-04-22
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax P… Recruiting

2024-517131-52-00 Relapsed/Refractory Chronic Lymphocytic Leukemia/Small 5 2025-11-03
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Recruiting

2023-509861-19-01 High-grade B-cell lymphoma (HGBL) 4 2025-09-30
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (… Recruiting

2023-510294-34-00 small lymphocytic lymphoma (SLL) 5 2025-06-12
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adult Patients Wi… Recruiting

2024-515593-27-00 relapsed or refractory mantle cell lymphoma (R/R MCL) 5 2025-05-08
Efficacy of Venetoclax in combination with Rituximab in Waldenström’s Macroglobulinemia Recruiting

2022-500574-34-00 Waldenström’s Macroglobulinemia 4 2025-03-21
Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis Recruiting

2023-504724-25-00 Primary Myelofibrosis 5 2024-10-16
Prospective, placebo-controlled clinical trial with Aconite Pain Oil in oncological patients under-going chemotherapy to prevent chemotherap… Recruiting

2022-502889-24-00 chemotherapy-induced polyneuropathy (CIPN) 5 2024-02-13
A trial to learn if odronextamab combined with lenalidomide is safe and works better than rituximab combined with lenalidomide in adult part… Recruiting

2022-503092-28-00 Relapsed/Refractory Follicular Lymphoma 5 2024-01-08
Venetoclax in combination with Ibrutinib and Rituximab or conventional chemotherapy (Bendamustine) and Ibrutinib and Rituximab in patients w… Recruiting

2022-501808-96-00 Mantle Cell Lymphoma 4 2023-05-15
A Randomized, Open-label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults wi… Recruiting

2022-501187-18-00 a. Diffuse large B-cell lymphoma (DLBCL) not otherwise 5 2023-04-24
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants Wi… Recruiting

2023-504599-10-00 Chronic lymphocytic leukemia recurrent 4 2022-03-29
FOLFOX before surgey compared to risk-adapted chemotherapy after surgery in patients with locally advanced rectal cancer and low risk for lo… Recruiting

2024-518077-34-00 locally advanced rectal cancer 5 2020-09-30
A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB… Ended

2023-506139-13-00 Treatment naïve patients with MF 5 2024-01-04
1L LUSPA VS ESA IN NTD LOW-RISK MDS PATIENTS Ended

2022-500430-29-00 Myelodysplastic Syndrome (MDS) 5 2023-10-11
Combination of Abemaciclib and endocrine therapy in hormone receptor positive HER2 negative locally advanced or metastatic breast cancer wit… Ended

2024-511209-49-00 Patients with hormone receptor positive HER2 negative l 6 2022-04-26
A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab… Ended

2022-500439-35-00 treatment-naive chronic lymphocytic leukemia 5 2021-02-11
Efficacy and safety of Carfilzomib in combination with Ibrutinib vs. Ibrutinib alone in Waldenström’s Macroglobulinemia (CZAR-1) Ended

2024-511929-60-00 Waldenström’s Macroglobulinemia 4 2021-01-28